profit from every €100 of sales.
€0€100
Ion Beam Applications SA
€16.02-2.08% today
+33.5% since Dec 18, 25
1-year low €12.001-year high €17.72
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €36.54 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ion Beam Applications SA sold, what it kept, and what it did with the cash.
Sales went from €361 million in 2022 to €620 million in 2025, with €12.7 million of profit last year.
SalesProfit
Ion Beam Applications SA vs. similar companies
Ion Beam Applications SA grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Ion Beam Applications SA | 36.5× · Expensive | ||
 Abbott Laboratories | 29.3× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 38.2× · Expensive | ||
 Edwards Lifesciences | 56.1× · Expensive |
AI analysis
An AI analyst reads Ion Beam Applications SA's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 361 | 467 | 498 | 620 | |
| 127 | 134 | 168 | 200 | |
| 5 | 5 | 10 | 22 | |
| 12 | 13 | 29 | 37 | |
| 6 | -9 | 9 | 13 | |
| 0.20 | -0.31 | 0.31 | 0.42 | |
| 35.1% | 28.8% | 33.7% | 32.2% | |
| 1.4% | 1.1% | 2.0% | 3.6% | |
| 1.7% | -2.0% | 1.9% | 2.1% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 624 | 598 | 616 | 691 |
| Cash | 158 | 109 | 72 | 65 |
| Total debt | 41 | 42 | 44 | 117 |
| Total liabilities | 508 | 491 | 505 | 563 |
| 116 | 106 | 111 | 127 | |
| 30 | 29 | 29 | 30 | |
| 0.8% | 0.9% | 8.7% | 7.4% | |
| 5.2% | -8.6% | 8.3% | 10.0% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 22 | -20 | -11 | -26 | |
| 7 | 12 | 7 | 13 | |
| 14 | -32 | -18 | -38 | |
| Dividends paid | 6 | 6 | 5 | 7 |
| 5 | – | – | 6 | |
| – | – | – | – |
Valuation
- 36.5×
- –
- 1.31
- 4.0×
- 0.8×
- –
- 14.2×
- -8.2%
- 2.7%
- 1.5%
Profitability
- 32.2%
- 3.6%
- 2.1%
- –
- 7.0%
- 4.2%
- –
- –
- –
- –
Growth
- +19.7%
- +27.9%
- –
- –
- +0.1%
Financial health
- 1.4×
- 0.92
- –
- 5.7×
- 0.99
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 42%of 948
Bottom 36%of 871
Bottom 37%of 560
Top 29%of 868
Bottom 14%of 985
1.5%of the share price, paid each year
On $1,000 invested$15a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
55.4% of its profit
Room to growStretchedMore than it earnsNews
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?Yahoo Finance · Oct 18, 2026Beam drops after updating Phase 1/2 trial data for gene-editing drugSeeking Alpha · Sep 8, 2026Beam Global outlines nearly $3M in rent savings over 5-year Yuma lease as Q2 revenue rises 174% q/qSeeking Alpha · Aug 20, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
17No pass
Philip Fisher
48No pass
Peter Lynch
73Pass
Joel Greenblatt
17No pass
Charlie Munger
18No pass
Terry Smith
18No pass
Questions about Ion Beam Applications SA
Is Ion Beam Applications SA a good stock to buy?
A business with weak numbers, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ion Beam Applications SA AI analysis
What does Ion Beam Applications SA do?
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It is in Medical Devices, based in Louvain-la-Neuve, Belgium, with 1,947 employees.
Does Ion Beam Applications SA pay a dividend?
Yes. At today's price the dividend is 1.5% a year, about 55% of its yearly profit. In 2025 it paid out €7.06 million in dividends.
Is Ion Beam Applications SA stock halal?
Yes. Ion Beam Applications SA passes our halal screen: its business is permitted and its debt is 25% of its market value, under the 30% limit. How we check
Who are Ion Beam Applications SA's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Ion Beam Applications SA's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.